SMS Pharmaceuticals Ltd — Call Transcript 2025

Nov 5, 2025

==> picture [240 x 160] intentionally omitted <==

Date: 05[th] November, 2025

To The Manager, Corporate Filings Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001.

Security Code: 532815

The Manager, Listing Compliance Department, National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Intimation of Investor’s Conference Call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing here with invitation for Investor’s Conference Call, scheduled to be held on Tuesday, 11[th] November, 2025 at 11:00 am, (IST), to discuss the Company’s financial results and performance for the second quarter and half year ended 30[th] September, 2025.

Please take into your records

Thanking you

Yours Faithfully

For SMS Pharmaceuticals Limited

THIRUMALES Digitally signed by THIRUMALESH TUMMA H TUMMA Date: 2025.11.05 19:36:19 +05'30' Thirumalesh Tumma Company Secretary

==> picture [145 x 71] intentionally omitted <==

Hyderabad, November 05, 2025: SMS Pharmaceuticals Ltd, a diversified and integrated pharmaceutical company specialising in APIs and intermediates, will announce its results for the second quarter ended September 30, 2025, on Saturday, November 08, 2025.

The results will also be available on the Company’s website, https://smspharma.com/. The Company will hold an earnings conference on Tuesday, November 11, 2025, at 11 am IST, where senior management will discuss its results and performance.

SMS Pharmaceuticals Q2 & H1 FY26 Earnings Call on Tuesday, November 11, 2025, at 11 am IST

Conference Dial-In Information:

Diamond Pass : Please click here to pre-register for the call

+91 22 6280 1254 Universal Numbers +91 22 7115 8043 Hong Kong – 800964448 Singapore – 8001012045 Toll Free Numbers UK – 08081011573 US – 18667462133

For any further information, please contact:

Company	Investor relatons
SMS Pharmaceuticals LtdMr. Thirumalesh TummaEmail: complianceofcer@smspharma.com	EqsponentMr. Aditya DutaEmail: smspharma.IR@eqsponent.com